Outcomes of Children With Enterobacteriaceae Bacteremia With Reduced Susceptibility to Ceftriaxone

Abstract

Our findings do not support the proposed clinical benefit of more conservative CLSI breakpoints. The revised breakpoints promote increased broad-spectrum β-lactam use. The need for lowered ceftriaxone breakpoints against Enterobacteriaceae in children needs to be reevaluated in larger prospective studies.